{
    "2018-10-10": [
        [
            {
                "time": "",
                "original_text": "【华泰医药代雯团队】乐普医疗 (300003.SZ, 买入) 事件点评：免疫治疗再下一城，外科器械锦上添花",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "免疫治疗",
                        "外科器械"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【乐普医疗】公告点评：参股美国Regenix公司，完善肿瘤免疫治疗布局",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "参股",
                        "Regenix",
                        "肿瘤免疫治疗"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物技术"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "乐普医疗：进一步布局肿瘤治疗 加码外科器械",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "肿瘤治疗",
                        "外科器械"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "仿制药概念走弱 华海药业跌停",
                "features": {
                    "keywords": [
                        "仿制药",
                        "华海药业",
                        "跌停"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "仿制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "总募资59.3亿元！创业板最大规模IPO结果揭晓 迈瑞医疗冲刺创业板一哥",
                "features": {
                    "keywords": [
                        "迈瑞医疗",
                        "IPO",
                        "创业板",
                        "募资"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}